Walleye Capital
QNCX icon

Walleye Capital’s Quince Therapeutics QNCX Stock Holding History

Walleye Capital’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-378
Closed -$168K – 3477
2022
Q2 		$168K Buy
+378
New +$267K ﹤0.01% 1582
2022
Q1 		– Sell
-686
Closed -$1.73M – 2536
2021
Q4 		$1.73M Buy
+686
New +$4.19M 0.05% 364

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Walleye Capital's QNCX Position: Q3 2022 in Review

Walleye Capital sold out of Quince Therapeutics (QNCX) in Q3 2022, closing a stake of 378 shares — an estimated $168K sold.

Walleye Capital first reported a position in QNCX in Q4 2021 and held it in 2 quarters. The position peaked at $1.73M in Q4 2021. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

  • Walleye Capital reported no remaining Quince Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Walleye Capital sold 378 Quince Therapeutics shares in Q3 2022, an estimated $168K.
  • Walleye Capital first reported a position in Quince Therapeutics in Q4 2021 and held it in 2 quarters.
  • Walleye Capital's Quince Therapeutics position peaked at $1.73M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on Walleye Capital's 13F filing for Q3 2022, filed 14 Nov 2022.